Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong General Hospital)
Cited by 89
Related Papers
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC
|Journal of Thoracic Oncology|2016|67
miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma
|Oncotarget|2016|43
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
|Journal of Hematology & Oncology|2011|33
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
|Cell Reports Medicine|2024|31